Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Tempus AI shows long-term promise with strong oncology testing and expanding market despite mixed Q1 results.
TEM
$57.31
+$0.06 +0.10%

Tempus AI shows long-term promise with strong oncology testing and expanding market despite mixed Q1 results.

Company Fundamentals
07 May 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Tempus AI reported mixed Q1 results with strong oncology testing but weakness in hereditary testing, slower revenue growth, yet improved gross margins and narrowing losses. The company achieved a record $1.1 billion total contract value and 126% net revenue retention, highlighting strong client loyalty and a growing market beyond oncology. Despite some near-term risks and slower growth, the stock remains attractive due to valuation contraction enhancing its risk/reward profile. The analyst maintains a buy rating based on Tempus AI's durable value proposition and expanding addressable market.

More News (TEM)

Tempus AI's healthcare data segment revenue jumps 40% YoY, targeting $500M+ in 2026.

Tempus AI's healthcare data segment revenue jumps 40% YoY, targeting $500M+ in 2026.

Tempus AI, Inc. reported a 40% year-over-year increase in its healthcare data segment revenue for Q1 2026, reaching $87 million. This growth is driven by a surge in MRD testing volume, which rose 500% YoY due to a partnership with Personalis for a re...

Analyst Insights
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App